Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06137703 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT06137703 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 52 participants.
The verdict
NCT06137703, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a period of about 7 weeks and the amount of drug in their blood will be assessed over the 24 hour period after each dose.
Interventions
- DRUG Zavegepant 100mg non-enteric coated soft gel capsule
- DRUG Zavegepant 100mg immediate release tablet
- DRUG Zavegepant 2 x 100mg immediate release tablets
- DRUG Zavegepant 4 x 25mg enteric coated soft gel capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06137703
The ClinicalTrials.gov registry entry for NCT06137703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zavegepant 100mg non-enteric coated soft gel capsule is the first listed.
NCT06137703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06137703 about?
NCT06137703 is a clinical study titled "A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers". This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a period of about 7 weeks and the amount of drug in their blood will be as...
What is the current status of trial NCT06137703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-08-24. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT06137703?
The interventions under investigation include: Zavegepant 100mg non-enteric coated soft gel capsule (DRUG), Zavegepant 100mg immediate release tablet (DRUG), Zavegepant 2 x 100mg immediate release tablets (DRUG), Zavegepant 4 x 25mg enteric coated soft gel capsule (DRUG).
Who is sponsoring clinical trial NCT06137703?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.